Table 2.
Comparison of the three anti-FXa groups according to the anticoagulation regimen and bleeding and thrombotic complications.
| Anti-FXa within the expected range (n = 22) | Out of expected range (n = 47) | p-value | ||
|---|---|---|---|---|
| Anti-FXa above the expected range (n = 10) | Anti-FXa below the expected range (n = 37) | |||
| Anticoagulant regimen, number (%) | ||||
| High-dose enoxaparin prophylaxis | 5 (29.4%) | 5 (29.4%) | 7 (41.1%) | 0.125 |
| Therapeutic enoxaparin | 12 (41.3%) | 5 (17.2%) | 12 (41.3%) | 0.215 |
| Therapeutic UFH infusion | 5 (21.7%) | 0 | 18 (78.2%) | 0.007 |
| Complications, number (%) | ||||
| Bleeding | 3 (13.6%) | 1 (10%) | 10 (27%) | 0.415 |
| Arterial thrombosis | 0 (4.5%) | 0 (0%) | 1 (2.7%) | 0.463 |
| VTE | 3 (13.6%) | 0 (0%) | 3 (8.1%) | 0.602 |
UFH: unfractionated heparin; VTE: venous thromboembolism.